Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07512063 · ClinicalTrials.gov registry record
A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 480
- Enrollment target
NCT07512063 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 480 participants.
The verdict
NCT07512063 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 480 participants
- Enrollment target
Study Summary
The aim of this study was to evaluate patient profiles, treatment patterns, and outcomes of hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (mBC) patients treated with a 1L cyclin dependent kinase 4/6 inhibitor (CDK4/6i) in the real-world setting.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2025-03-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07512063
The ClinicalTrials.gov registry entry for NCT07512063 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07512063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07512063 about?
NCT07512063 is a clinical study titled "A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors". The aim of this study was to evaluate patient profiles, treatment patterns, and outcomes of hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (mBC) patients treated with a 1L cyclin dependent kinase 4/6 inhibitor (CDK4/6i) in the real-...
What is the current status of trial NCT07512063?
This trial is currently completed. The enrollment target is 480 participants. The study started on 2024-10-08. Estimated completion is 2025-03-17.
Who is sponsoring clinical trial NCT07512063?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.